Mufaddal Mahesri

Research Specialist/ Epidemiologist @

[JAMA Internal Medicine @JAMAInternalMed]

Isotretinoin under Risk Evaluation and Mitigation Strategy reduced pregnancy incidence by 70% to 80% compared to topical retinoids. https://t.co/oHoIKMCj8n @mmahesri

[Mufaddal Mahesri @mmahesri]

@Rishidesai11 If you're at #ASH23, come check out our SCD research using #RWE today (December 10th) at Poster # 3674

[Mufaddal Mahesri @mmahesri]

The FDA-approval for gene-editing therapies for SCD is a historic moment. Truly curative potential if the early clinical response is sustained long-term.
We use #RWE to offer some context for the efficacy of gene-therapies in SCD.
#ASH2023 poster # 3674.

https://t.co/n0Fu2Zq1to

[Mufaddal Mahesri @mmahesri]

Presented is a great thread by @Rishidesai11 here:
https://t.co/2l1QG83z9J

[Rishi J Desai @Rishidesai11]

FDA Approval of Exa Cel- the CRISPR based therapy for sickle cell- is a significant moment in the history of medicine!!

https://t.co/DPzg73gQ6l

Especially gratifying to see this as we contributed data in a small but meaningful way to this BLA!

A quick thread!

CC: @mmahesri

[Rishi J Desai @Rishidesai11]

FDA Approval of Exa Cel- the CRISPR based therapy for sickle cell- is a significant moment in the history of medicine!!

https://t.co/DPzg73gQ6l

Especially gratifying to see this as we contributed data in a small but meaningful way to this BLA!

A quick thread!

CC: @mmahesri

[Julie Lauffenburger @jlauffen]

Pleased to share new work on identifying predictors of elevated long-term #gout spending for intervention, with @SeoyoungCKim & @mmahesri, chosen to be highlighted today in @BrighamWomens "Brigham on a Mission": https://t.co/r9PYOgthAR
@arhritis_care Pub: https://t.co/05NRlzpvDy

[Julie Lauffenburger @jlauffen]

New @C4HDS paper, co-led w/ @niteeshchoudhry: providing answers to some real-world questions we had about adaptive trials when designing/launching our NUDGE-EHR trial (https://t.co/rb3lmP774i)

Huge thanks to co-authors @argMaxRusso, @LorenzoTrippa, Steffen Ventz & Bob Glynn

[Rishi J Desai @Rishidesai11]

** New paper **

First results of our DREAM study are out @JAMANetworkOpen. We believe that this is an important step forward in principled use of routinely collected healthcare data in drug repurposing research. Read on if this is of interest /1

https://t.co/814Qt6OX6y

[JAMA Network Open @JAMANetworkOpen]

This cohort study found initiation of JAK-, IL-6-, or TNF-inhibitors in patients with RA was not associated with lower risk of Alzheimer disease and related dementia, compared with the T-cell activation inhibitor abatacept. @RishiDesai11 https://t.co/vbzvyqTRnQ

[Rishi J Desai @Rishidesai11]

We externally validated this probabilistic phenotyping approach using data from IBM explorys (also published last week), led by @mmahesri

https://t.co/yaFCQuYqyu

[Rishi J Desai @Rishidesai11]

** New paper **

We noted robust effectiveness of ARNI v RASi in older HFrEF patients
https://t.co/hekKwLSyNJ

This is ~5 years in the making with key building blocks along the way to enable rigorous evaluation of HF outcomes in claims. A quick summary, follow along if interested

[Julie Lauffenburger @jlauffen]

Beyond excited to share the design & rationale publication about our recently-launched NUDGE-EHR trial in @ImplementSci (co-led w/ @niteeshchoudhry), representing several years of work by many great co-investigators and others @C4HDS
https://t.co/23MNWn4qFL

[Madhav Thambisetty @MadhavThambiset]

https://t.co/RQZrpTmUmK

A slightly inaccurate but still interesting blog post on our DREAM study

[Rishi J Desai @Rishidesai11]

Glad to share the design and rationale paper for our DREAM study- definitely one of the most challenging and ambitious projects I've been a part of..

https://t.co/4ozGcLFhfe

[NIHCM @NIHCMfoundation]

A new study by @jlauffen @mmahesri @niteeshchoudhry offers insights on reducing health care costs.

Learn more: https://t.co/ocId0Frfa6

#NIHCM #healthcare #Health

[John Z. Ayanian @jzayanian]

My @JAMAHealthForum commentary this week on looming fiscal challenge that awaits new President & Congress in light of @JAMANetworkOpen study by @jlauffen @mmahesri @niteeshchoudhry on #Medicare spending patterns

[Mufaddal Mahesri @mmahesri]

Among SCD patients who underwent BMT, we assessed safety/effectiveness of this curative therapy during routine care in the US.
Critical findings help understand the limited use of BMT in SCD.
Thank you @Rishidesai11 & team for this important contribution: https://t.co/Fi56uK0uJZ

[Mufaddal Mahesri @mmahesri]

@Rishidesai11 This is awesome! Congrats, Rishi!

[Rishi J Desai @Rishidesai11]

** New paper **

When using Medicare claims to stratify HF patients into reduced or preserved EF in the absence of measured EF values, what types of populations do we end up with? Check out our new paper in @amjmed

https://t.co/Er7AgxvdTx

a short thread 0/

[Vivek Garg @vgargMD]

In a world where 6-12 month “ROI” dominates, we need to look farther out for emerging trends we can help patients with.

This study by @jlauffen @mmahesri @niteeshchoudhry starts to do just that (2 year window).

By looking downstream, we can invest more upstream.